Literature DB >> 18221597

Diagnosis and management of viral myocarditis.

William H Frishman1, Joshua Zeidner, Nauman Naseer.   

Abstract

Myocarditis has been shown to be a common cause of cardiomyopathy; it is believed to account for 25% of all cases of heart failure in humans. Unfortunately, the disease is difficult to detect clinically before a myopathic process ensues. Treatment of myocarditis-induced heart failure includes the standard regimen of diuretics, digoxin, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and beta-adrenergic blockers. Treatment of myocarditis itself is dependent on the etiology of the illness. Additional treatments under investigation for viral and autoimmune myocarditis include immunosuppressants, nonsteroidal anti-inflammatory agents, immunoglobulins, immunomodulators, and antivirals, with no specific therapy having a real advantage over standard treatment for heart failure. Despite advances in treatment, more work needs to be done in the early detection of myocarditis. In addition, better means need to be established for distinguishing between viral and noninfectious autoimmune forms of the disease so that appropriate treatment can be instituted.

Entities:  

Year:  2007        PMID: 18221597     DOI: 10.1007/s11936-007-0040-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  78 in total

1.  Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results.

Authors:  M Mirić; J Vasiljević; M Bojić; Z Popović; N Keserović; M Pesić
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

2.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.

Authors:  R E McCarthy; J P Boehmer; R H Hruban; G M Hutchins; E K Kasper; J M Hare; K L Baughman
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

Review 3.  Peripartum cardiomyopathy.

Authors:  Angela Ro; William H Frishman
Journal:  Cardiol Rev       Date:  2006 Jan-Feb       Impact factor: 2.644

4.  Cellular immune mechanisms in myosin-induced myocarditis.

Authors:  C Pummerer; G Grässl; N Neu
Journal:  Eur Heart J       Date:  1995-12       Impact factor: 29.983

5.  High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity.

Authors:  A Matsumori; H Igata; K Ono; A Iwasaki; T Miyamoto; R Nishio; S Sasayama
Journal:  Jpn Circ J       Date:  1999-12

Review 6.  Cardiac complications of human immunodeficiency virus infection: diagnostic and therapeutic considerations.

Authors:  A Arshad; A Bansal; R C Patel
Journal:  Heart Dis       Date:  2000 Mar-Apr

7.  Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets.

Authors:  C Kishimoto; C S Crumpacker; W H Abelmann
Journal:  J Am Coll Cardiol       Date:  1988-11       Impact factor: 24.094

8.  Immunosuppressive treatment for inflammatory cardiomyopathy: meta-analysis of randomized controlled trials.

Authors:  Chao Liu; Junmin Chen; Kunshen Liu
Journal:  Int Heart J       Date:  2005-01       Impact factor: 1.862

Review 9.  Immunomodulation: a new horizon for medical treatment of heart failure.

Authors:  S Sasayama; A Matsumori; Y Matoba; S Matsui; T Yamada; T Shioi; Y Sato; K Doyama; C Kishimoto
Journal:  J Card Fail       Date:  1996-12       Impact factor: 5.712

10.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.